The role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agents
Andreas M ReimoldDallas Veterans Affairs Medical Center and Rheumatic Diseases Division, University of Texas Southwestern Medical Center, Dallas, TX, USAAbstract: Adalimumab (ADA) is a biologic medication that dampens inflammatory pathways by binding to the cytokine tumor necrosis factor alpha. The...
Guardado en:
Autor principal: | Reimold AM |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/cfc3051d236445f0af47fea6195a5b7a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Long-term use of adalimumab in the treatment of rheumatic diseases
por: Charalampos Papagoras, et al.
Publicado: (2009) -
COVID-19 and Autoimmune/Autoinflammatory Rheumatic Disease Patients: Lessons Learned and Questions Anticipating Answers
por: Athanasios-Dimitrios Bakasis, et al.
Publicado: (2021) -
Efficacy and safety of adalimumab in ankylosing spondylitis
por: Mounach A, et al.
Publicado: (2014) -
Long-term treatment of rheumatoid arthritis with adalimumab
por: Murdaca G, et al.
Publicado: (2013) -
Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis
por: Fabrizio Cantini, et al.
Publicado: (2009)